Overview

Electra Therapeutics Inc., a San Francisco‑based biotechnology company, filed a registration statement with the U.S. Securities and Exchange Commission on 29 August 2026 to conduct an initial public offering on the Nasdaq Global Select Market under the ticker symbol ETRA. The offering is intended to raise capital to advance its clinical‑stage pipeline of drugs targeting immune‑mediated diseases and cancer.

Lead Product and Designations

The company’s lead candidate, ipsoprubart, is a monoclonal antibody aimed at treating secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyper‑inflammatory syndrome with limited approved therapies and poor survival rates. Ipsoprubart has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration and PRIORITY MEDICINE designation by the European Medicines Agency.

Financial Position

For the fiscal year ended 31 December 2025, Electra reported a net loss of $61.975 million, compared with a net loss of $24.786 million in 2024. Research and development expenses increased to $50.387 million in 2025 from $19.267 million in the prior year. As of 30 June 2026, the company held $97.725 million in cash, cash equivalents and marketable securities.

Clinical Development Pipeline

Electra is conducting a global Phase 2/3 registrational trial of ipsoprubart in newly diagnosed sHLH patients, with enrollment expected to be completed in the second half of 2027. In addition, the firm is advancing ELA822, another monoclonal antibody designed to selectively deplete activated T cells for potential use across chronic T‑cell‑mediated immune and inflammatory diseases. A Phase 1 trial of ELA822 in healthy volunteers was initiated in Europe in August 2026.

Offering Details

The underwriting syndicate comprises Jefferies, TD Cowen, Evercore ISI, and Cantor. The company did not disclose the number of shares to be offered or the anticipated price range. On a pro‑forma basis, following the automatic conversion of all outstanding redeemable convertible preferred stock, Electra had 59.158 million shares of common stock outstanding as of 30 June 2026.

Additional Information

No further terms of the offering were provided in the filing. The filing was generated with AI assistance and reviewed by an editor.